Mon, Sep 11, 2023 | By Cryoport Team
For over 10 years, Cryoport Systems has been utilizing our near real-time condition monitoring solution that offers precise location information on shipments. With such vast experience, we’ve used...
Wed, Aug 16, 2023 | By Cryoport Team
Clean and validated cryogenic packing is essential to compliantly ship biological material. But how can you be sure that your supply chain management partner understands the importance of cleanliness...
Wed, Jul 26, 2023 | By Cryoport Team
Wed, May 31, 2023 | By Cryoport Team
When it comes to choosing a cell and gene therapy shipping partner, not all providers are created equal. To select the best partner for your organization, it’s important to consider how their...
Fri, Apr 07, 2023 | By Cryoport Team
Cryoport Systems has extended its expertise in temperature-controlled supply chain solutions with vein-to-vein BioServices offerings. BioServices expands our supply chain solutions in order to better...
Tue, Mar 07, 2023 | By Cryoport Team
At Cell&Co BioServices, a Cryoport Systems company, new product innovations are not adopted without significant testing. Recently our team dedicated 3 months to the creation and certification of a...
Tue, Feb 28, 2023 | By Cryoport Team
Cryoport Systems has grown to become a leader in the cell and gene therapy industry since its founding in 1999. Throughout those 20+ years, we've seen how both the growth and transformation of the...
Tue, Dec 13, 2022 | By Cryoport Team
In this video documentary, American Pharmaceutical Review and Pharmaceutical Outsourcing magazine spoke with Cryoport Systems' CEO, Mark Sawicki, VP Global BioServices, Rob Jones, and fellow industry...
Wed, Nov 30, 2022 | By Cryoport Team
Cryoport combines its expertise in temperature-controlled supply chain solutions to develop a comprehensive offering of vein-to-vein services, one of which includes Kit Production. From clinical to...
Wed, Oct 19, 2022 | By Cryoport Team
Companies vying to be the first to market with breakthrough treatments have a great deal riding on the success of their efforts. Incorporating innovative processes, ethical considerations, assuring...
Thu, Oct 13, 2022 | By Cryoport Team
Many biopharmaceutical companies, academic institutions, and manufacturing sites often need to move their valuable life-saving therapies and research materials locally for a variety of reasons, such...
Mon, Aug 29, 2022 | By Cryoport Team
As cell and gene therapies are rapidly moving beyond clinical trials and into commercial markets, the safe and effective delivery of these life-saving treatments needs to be a priority for advanced...
Mon, Aug 22, 2022 | By Rob Jones, Vice President of Global BioServices
Cryoport Systems’ highly anticipated Global Supply Chain Centers have been operational for a few months, and customers continue to move biopharmaceutical materials into our Houston, Texas and Morris...
Wed, Jul 20, 2022 | By Cryoport Team
In support of Cord Blood Awareness Month, Cryoport Systems’ partner, Be The Match BioTherapies®, led a webinar focused on the untapped potential and benefits of cord blood for prospective therapies....
Mon, Jun 06, 2022 | By Rob Jones, Vice President of Global BioServices
We are quickly approaching the Grand Opening of our first two Global Supply Chain Centers in Houston, TX on June 14th and Morris Plains, NJ on June 16th, 2022.
Although we are about to officially...
Thu, May 19, 2022 | By Cryoport Team
At Cryoport Systems, we are continuously striving to align with the latest science and technology advancements in our products and services, integrating the most advanced packaging, informatics, and...
Fri, Feb 11, 2022 | By Quin Waddell, Director of Monitoring Solutions
The future for global advanced therapy shipments requiring critical near real-time chain of custody, chain of condition and Chain of Compliance® reporting will soon face a significant technology...
Wed, Dec 15, 2021 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems
Update: President Biden signed Proclamation 10326 To Modify the Harmonized Tariff Schedule of the United States and for Other Purposes on December 23rd, 2021. Thus, Customs and Border Protection...
Mon, Dec 06, 2021 | By Dave Wilson, Vice President EMEA
Biotech companies continue to innovate cutting-edge therapeutics, and the companies that support their efforts continue to strive for best practices as these new therapies advance and evolve. In the...
Tue, Nov 16, 2021 | By Rob Jones, Vice President of Global BioServices
Cryoport Systems is making significant progress since the last update on launching our Global BioServices in Houston, Texas and Morris Plains, New Jersey. These two prime locations were chosen...
Mon, Sep 20, 2021 | By Gregory Stevens, Executive Director - Business Operations
Are you experiencing the following 10 problems with your current logistics courier?
Wed, Sep 08, 2021 | By Rob Jones, Vice President of Global BioServices
One of the challenges facing the cell and gene therapy industry, as it grows and matures, is the development of robust supply chains to support the increase in clinical trials and the...
Fri, Feb 12, 2021 | By Cryoport Team
While the pandemic continues to disrupt many industries, including regenerative medicine, it’s not all bad news -- in fact, there are likely some bright spotsahead for the industry this year.
Mon, Jan 11, 2021 | By Cryoport Team
2020 was an incredibleyear of growth for Cryoport, Inc. The acquisitions of CRYOPDP and MVE Biological Solutions dramatically increased our global network and capabilities, and we achieved a new...
Americas • EMEA • APAC
Sales • +1 949.470.2300 | Support • +1 949.470.2305
©2023 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC
